Barinthus Bio Provides Update on Proposed Combination with Clywedog TherapeuticsGERMANTOWN, Md., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (
NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today provided an update regarding the anticipated closing of its proposed combination with Clywedog Therapeutics, Inc. (“Clywedog”) in an all-stock transaction.
Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate DevelopmentsGERMANTOWN, Md., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (
NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today announced its financial results for the quarter ended June 30, 2026, and provided an overview of the Company’s corporate developments. Barinthus Bio is an immunology and inflammation (“I&I”) company focused on developing therapies that promote immune tolerance with curative potential.
